Approval · Notice of Compliance 29925 · 2023
SUMATRIPTAN INJECTION, USP: Notice of Compliance 29925
Issued January 18, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29925
- Date
- January 18, 2023
- Company
- Sterimax Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN INJECTION, USP | 02443953 | Approved |
Medicinal ingredients
- SUMATRIPTAN 6 MG per 0.5ML